Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck KGaA builds presence in China

by Alex Scott
November 14, 2016 | A version of this story appeared in Volume 94, Issue 45

Merck KGaA plans to spend $90 million on a facility in Nantong, China, that supplies pharmaceutical services and products such as high-purity inorganic salts and cell culture media. The firm just inaugurated a $200 million facility in Nantong for manufacturing pharmaceuticals on China’s Essential Drug List. Merck claims it is the first multinational to operate such a plant in China. The first of the drugs are set to be delivered to patients in the second half of 2017.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.